Stock Events

Stock Events

Voyager Therapeutics 

€3.15
0
-€0.2-5.85% Friday 19:56

Statistics

Day High
3.37
Day Low
3.12
52W High
4.54
52W Low
2.36
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VT6.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap26.03B
Biogen focuses on neurological diseases, directly competing in Voyager's therapeutic areas, including gene therapy.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics and gene therapy for rare diseases, similar to Voyager's mission.
PTC Therapeutics
PTCT
Mkt Cap5.7B
PTC Therapeutics is involved in the development of genetically targeted therapies, including for neurological disorders, competing with Voyager.
Novartis
NVS
Mkt Cap297.32B
Novartis has a strong presence in gene therapy, particularly with its acquisition of AveXis, making it a direct competitor in the gene therapy space.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has invested heavily in gene therapy for rare diseases, positioning it as a competitor in the same field as Voyager.
Abeona Therapeutics
ABEO
Mkt Cap274.98M
Abeona Therapeutics focuses on developing gene and cell therapies for serious diseases, making it a competitor in the gene therapy market.

About

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Robert W. Hesslein
Employees
101
Country
United States
ISIN
US92915B1061

Listings

STU
DE
VT6.STU
MX
MX
VYGR.MX
XNAS
US
VYGR
F
DE
VT6.F

0 Comments

Share your thoughts

FAQ

What is Voyager Therapeutics stock price today?▼
The current price of VT6.STU is €3.15 EUR — it has decreased by -5.85% in the past 24 hours. Watch Voyager Therapeutics stock price performance more closely on the chart.
What is Voyager Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Voyager Therapeutics stocks are traded under the ticker VT6.STU.
Is Voyager Therapeutics stock price growing?▼
VT6.STU stock has fallen by -7.18% compared to the previous week, the month change is a -24.4% fall, over the last year Voyager Therapeutics has showed a +14.28% increase.
How many employees does Voyager Therapeutics have?▼
As of April 11, 2026, the company has 101 employees.
In which sector is Voyager Therapeutics located?▼
Voyager Therapeutics operates in the Healthcare sector.
When did Voyager Therapeutics complete a stock split?▼
Voyager Therapeutics has not had any recent stock splits.
Where is Voyager Therapeutics headquartered?▼
Voyager Therapeutics is headquartered in Cambridge, United States.